Cocrystal Pharma Inc(COCP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 4:00 PM ET (Korea 10/22 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.76 | Insider Own | 33.53% | Shs Outstand | 13.8M | Perf Week | -9.27% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 34.48% | Insider Trans | 1.33% | Shs Float | 12.8M | Perf Month | -20.71% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.18 | Inst Own | 5.77% | Short Float | 1.37% | Perf Quarter | 2.55% |
| Income | -0.01B | P/S | 55.07 | EPS this Y | 7.05% | Inst Trans | 15.22% | Short Ratio | 3 | Perf Half Y | -35.81% |
| Sales | 0.00B | P/B | 12.46 | EPS next 5Y | 6.87% | ROA | -151.1% | Short Interest | 0.18M | Perf YTD | -3.62% |
| Book/sh | 0.08 | P/C | 8.11 | EPS past 3/5Y | 45.26% 17.9% | ROE | -311.68% | 52W High | -53.51% ($2.03) | Perf Year | -10.98% |
| Cash/sh | 0.12 | P/FCF | - | Sales past 3/5Y | - | ROIC | -488.83% | 52W Low | 24.16% ($0.76) | Perf 3Y | -44.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 38.55% | Gross Margin | 37.27% | Volatility(W/M) | 6.52% 5.91% | Perf 5Y | -91.9% |
| Dividend TTM | - | EV/Sales | 52.34 | Sales Y/Y TTM | - | Oper. Margin | -3063.64% | ATR (14) | 0.06 | Perf 10Y | -99.47% |
| Dividend Ex-Date | - | Quick Ratio | 1.24 | EPS Q/Q | -13.61% | Profit Margin | -3011.52% | RSI (14) | 28.79 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.24 | Sales Q/Q | - | SMA20 | -12.5% ($1.07) | Beta | 1.59 | Target Price | $7 |
| Payout | - | Debt/Eq | 1.29 | Earnings | 2026/08/17 | SMA50 | -15.9% ($1.12) | Rel Volume | 0.13 | Prev Close | $0.94 |
| Employees | 10 | LT Debt/Eq | 0.95 | EPS/Sales Surpr. | -39.39% - | SMA200 | -14.75% ($1.1) | Avg Volume(3M) | 0.06M | Price | $0.94 |
| IPO | 2008/4/1 | Option/Short | No/Yes | Trades | 80 | Volume | 7,550 | Change | 0.07% |
🧬 Cocrystal Pharma, Inc. (–) is a clinical-stage biotechnology company that takes a structure-based approach to targeting viral replication enzymes. The company is developing oral antivirals aimed at the replication enzymes of major RNA viruses, including norovirus, influenza, coronavirus, and hepatitis C. Its lead candidate, CDI-988, is being developed as the world's first oral norovirus protease inhibitor candidate.
Over the past 1 year, on the lower side
54% below its 1-year high.
Traded less than usual. That is 13% of its average volume.
COCP has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +7.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $5,507. Peers typically go for $1,173.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #470 of 595 in the industry
Based on market cap of $18M.
QNTM#467 Quantum BioPharma Ltd $19M PER - 
MRKR#468 Marker Therapeutics Inc $19M PER - 
NEUP#469 Neuphoria Therapeutics Inc $19M PER - COCP#470 Cocrystal Pharma Inc $18M PER - 
PBM#471 Psyence Biomedical Ltd $17M PER - 
FAQ
What kind of company is COCP?
COCP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of COCP?
The market cap of COCP is approximately $18M, ranking 5,252 within its sector.
What is the 52-week high and low for COCP?
COCP has recorded a 52-week high of $2.03 and a low of $0.76.
